Wyeth/Amgen Enbrel Brand Team To Be Created Under Amended Deal
Executive Summary
Wyeth-Ayerst and Amgen will form a joint Enbrel brand management team under the amended co-promotion agreement for the TNF inhibitor worked out prior to Amgen's acquisition of Immunex
You may also be interested in...
Immunex Enbrel Psoriatic Arthritis 12-Month Data To Follow sBLA Approval
Immunex plans to submit 12-month, open-label Enbrel data in psoriatic arthritis patients following FDA's Jan. 16 approval of etanercept for the supplemental indication
Amgen Enbrel Projections Include 3-Month Cushion For Immunex Plant
Amgen's financial forecasts for the Immunex acquisition include a three-month cushion on the start-up date for a new production plant for Enbrel.
Leukine Is Divestment Candidate In Amgen/Immunex Deal
Immunex' Leukine is available for licensing as part of Amgen's acquisition of the biotech company